{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:31Z","timestamp":1787851351198,"version":"build-2784847793"},"reference-count":188,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006508","name":"Dhont Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019757","name":"Gloria Borges WunderGlo Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019757","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA014089"],"award-info":[{"award-number":["P30CA014089"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108304","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:46:59Z","timestamp":1784227619000},"page":"108304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAF"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6709-8265","authenticated-orcid":false,"given":"M.","family":"Bartolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Algaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-9568","authenticated-orcid":false,"given":"H.-J.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108304_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-023-04522-x","article-title":"Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2026.108304_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-025-04117-1","article-title":"Consensus Molecular Subtypes (CMS) classification: a progress towards subtype-driven treatments in colorectal cancer","volume":"24","author":"Kantha","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.108304_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.2020.38.4_suppl.188","article-title":"Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: an analysis of 7,828 patients in the ARCAD database","volume":"38","author":"Yin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114160","article-title":"Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: an ARCAD pooled analysis","volume":"207","author":"Cohen","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2026.108304_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108304_bib8","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib11","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/theoncologist.2019-0189","article-title":"A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer","volume":"24","author":"Sonbol","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108304_bib16","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-15-2783","article-title":"TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies","volume":"22","author":"van der Velden","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib17","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/onc.2014.416","article-title":"Oncogenic KRAS signalling promotes the Wnt\/\u03b2-catenin pathway through LRP6 in colorectal cancer","volume":"34","author":"Lemieux","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2026.108304_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/ijms22010130","article-title":"Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements","volume":"22","author":"Malki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108304_bib19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","article-title":"Molecular origins of cancer: molecular basis of colorectal cancer","volume":"361","author":"Markowitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14737140.2025.2519860","article-title":"The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors","volume":"25","author":"Molavand","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib22","article-title":"Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.108304_bib23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.37349\/etat.2024.00243","article-title":"Antibody-drug conjugates combinations in cancer treatment","volume":"5","author":"Pretelli","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib25","article-title":"Pertuzumab plus trastuzumab for treatment-refractory HER2-amplified metastatic colorectal cancer: comparison of the MyPathway trial with a real-world external control arm","volume":"6","author":"Narita","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.esmoop.2026.108304_bib26","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib27","first-page":"256","article-title":"Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib28","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108304_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib30","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib32","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib33","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib34","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2174\/0115680096260614231115192343","article-title":"CT109-SN-38, a novel antibody-drug conjugate with dual specificity for CEACAM5 and 6, elicits potent killing of pancreatic cancer cells","volume":"24","author":"Cardenas","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.esmoop.2026.108304_bib35","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib36","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib38","article-title":"Phase 1\/2 study of tusamitamab ravtansine in patients with advanced solid tumors: pooled safety analysis of corneal adverse events","volume":"41","author":"Gazzah","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib39","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-09-0586","article-title":"CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates","volume":"15","author":"Govindan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib40","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s10147-025-02784-4","article-title":"Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors","volume":"30","author":"Muro","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib41","article-title":"An open-label phase 1 study to investigate SGNCEACAM5C\/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001)","volume":"42","author":"Patnaik","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-0442","article-title":"Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130)","volume":"17","author":"Sharkey","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib43","article-title":"PROCEADE PanTumor: a phase 1b\/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors","volume":"43","author":"Wainberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib44","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","article-title":"Tusamitamab ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens","volume":"3","author":"Tabernero","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108304_bib45","article-title":"573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): updated results from a phase I trial","volume":"35","author":"Boni","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12394","article-title":"TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis","volume":"10","author":"Foersch","year":"2024","journal-title":"J Pathol Clin Res"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib48","article-title":"TROPION-PanTumor03: phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced\/metastatic solid tumors","volume":"41","author":"Janjigian","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib49","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib50","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.annonc.2023.04.182","article-title":"P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced\/metastatic solid tumours: substudies in gastric and colorectal cancer","volume":"34","author":"Oaknin","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib51","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-TROP-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib52","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","article-title":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: a first-in-human phase 1 study","volume":"43","author":"Zhong","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2026.108304_bib53","article-title":"Efficacy and safety of sacituzumab govitecan in solid tumors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib54","doi-asserted-by":"crossref","first-page":"S692","DOI":"10.1016\/j.annonc.2022.07.479","article-title":"341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: an exploratory analysis of the TRIBE2 study","volume":"33","author":"Conca","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib55","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.esmoop.2026.108304_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112499","article-title":"Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: key points for radiologists","volume":"194","author":"Cereser","year":"2026","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.esmoop.2026.108304_bib57","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/cncr.35349","article-title":"The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and\/or pneumonitis: a systematic review and single-arm meta-analysis","volume":"130","author":"Li","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2026.108304_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0334513","article-title":"Hematological toxicity of anti-tumor antibody-drug conjugates: a retrospective pharmacovigilance study using the FDA adverse event reporting system","volume":"20","author":"Rao","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108304_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib61","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105015","article-title":"Antibody-drug conjugates in oncology: a spotlight on overcoming resistance","volume":"217","author":"Xu","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2026.108304_bib64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108304_bib65","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib66","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13046-023-02729-7","article-title":"Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches","volume":"42","author":"Wang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib68","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","article-title":"Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody-drug conjugates","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib69","article-title":"Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation\/amplified metastatic colorectal cancer refractory to at least two standard regimens: a prospective, exploratory, single-arm study","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib70","article-title":"Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation\/amplified metastatic colorectal cancer refractory to at least two standard regimens: a prospective, exploratory, single-arm study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib71","article-title":"Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"issue":"12 suppl","key":"10.1016\/j.esmoop.2026.108304_bib72","article-title":"Abstract B130: Phase 1 study of zanidatamab zovodotin (ZW49): safety profile and recommended dose (RD) in patients with human epidermal growth factor 2 (HER2)-positive solid cancers","volume":"22","author":"Oh","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"3 suppl","key":"10.1016\/j.esmoop.2026.108304_bib73","article-title":"An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced\/metastatic colorectal cancer (CRC)","volume":"39","author":"Raghav","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib74","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","article-title":"DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: preliminary results from the phase 1\/2a trial","volume":"43","author":"Lisberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib75","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-15-2474","article-title":"Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies","volume":"22","author":"Almhanna","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2016.10.007","article-title":"Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies","volume":"170","author":"Almhanna","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib77","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1200\/JCO.2024.42.16_suppl.6013","article-title":"Preliminary results of phase I\/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors","volume":"42","author":"Ruan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib78","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2024.42.16_suppl.3515","article-title":"First-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: results in colorectal cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib79","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib80","article-title":"Phase 1 trial of a novel C\u2019Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FR\u03b1)","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib81","article-title":"Phase 1\/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and\/or metastatic solid tumors","volume":"41","author":"Call","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib82","article-title":"A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors","volume":"43","author":"Lemech","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib83","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2024.42.16_suppl.3023","article-title":"A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas","volume":"42","author":"Lemech","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2 suppl","key":"10.1016\/j.esmoop.2026.108304_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2026.44.2_suppl.121","volume":"44","author":"Yin","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib85","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108304_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib87","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cancers17101665","article-title":"Petosemtamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and leucine-rich G repeat-containing protein-coupled receptor (LGR5) designed for broad clinical applications","volume":"17","author":"Lundberg","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.108304_bib88","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2023.41.4_suppl.111","article-title":"A phase1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer","volume":"41","author":"Lim","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib89","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10637-018-0665-y","article-title":"A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors","volume":"37","author":"Jimeno","year":"2019","journal-title":"Invest New Drugs"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.108304_bib90","article-title":"ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors\u2014Colorectal Cancer Cohort (trial in progress)","volume":"41","author":"Oberstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12 suppl","key":"10.1016\/j.esmoop.2026.108304_bib91","first-page":"P02","article-title":"Abstract P02-03: Phase Ia\/Ib dose-escalation study of ABL001 (CTX-009, bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors","volume":"20","author":"Lee","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib92","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108304_bib93","article-title":"746P A 2-year follow-up of zanidatamab (Zani) + mFOLFOX6 \u00b1 bevacizumab (Bev) in first-line (1L) treatment of patients (Pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic colorectal cancer (mCRC)","volume":"36","author":"Rha","year":"2025","journal-title":"Ann Oncol"},{"issue":"3 suppl","key":"10.1016\/j.esmoop.2026.108304_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2024.42.3_suppl.135","article-title":"Amivantamab monotherapy in relapsed\/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b\/2 study","volume":"42","author":"Oberstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2 suppl","key":"10.1016\/j.esmoop.2026.108304_bib95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2026.44.2_suppl.166","article-title":"Amivantamab plus FOLFOX or FOLFIRI in RAS\/BRAF wild-type metastatic colorectal cancer: long-term follow-up from the phase 1b\/2 OrigAMI-1 study","volume":"44","author":"Chen","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.108304_bib96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2023.41.4_suppl.115","article-title":"A phase Ia\/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers","volume":"41","author":"Harding","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib97","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"3","author":"Herpers","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib98","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","article-title":"Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist","volume":"20","author":"Garc\u00eda-Mart\u00ednez","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib99","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108304_bib101","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/annonc\/mdt231","article-title":"Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings","volume":"24","author":"Kubicka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108304_bib103","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib104","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib105","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib106","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib107","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108304_bib108","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/ijms25021263","article-title":"Key proteins of replication stress response and cell cycle control as cancer therapy targets","volume":"25","author":"Khamidullina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108304_bib109","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1634\/theoncologist.2015-0319","article-title":"Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer","volume":"21","author":"Leichman","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108304_bib110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/ijc.70191","article-title":"Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: results from the drug rediscovery protocol","volume":"158","author":"Spiekman","year":"2026","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib111","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175369","article-title":"Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.esmoop.2026.108304_bib112","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1158\/1078-0432.CCR-22-0875","article-title":"Targeting the DNA damage response pathways and replication stress in colorectal cancer","volume":"28","author":"Durinikova","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108304_bib113","article-title":"Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors","volume":"85","author":"Ulahannan","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib114","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.21.01435","article-title":"Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","volume":"39","author":"Seligmann","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib115","article-title":"A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors","volume":"40","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib116","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3390\/ijms23084264","article-title":"Development and evolution of DNA-dependent protein kinase inhibitors toward cancer therapy","volume":"23","author":"Matsumoto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108304_bib117","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","article-title":"A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer","volume":"30","author":"Romesser","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib118","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41388-021-02162-0","article-title":"An mRNA expression-based signature for oncogene-induced replication-stress","volume":"41","author":"Guerrero Llobet","year":"2022","journal-title":"Oncogene"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.108304_bib119","article-title":"504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)","volume":"35","author":"Wainberg","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib121","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fimmu.2020.00369","article-title":"Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer","volume":"11","author":"Picard","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.108304_bib122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41419-024-06598-6","article-title":"Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer","volume":"15","author":"Xiao","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.esmoop.2026.108304_bib123","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms22168470","article-title":"Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108304_bib124","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib125","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1200\/JCO.2025.43.16_suppl.3579","article-title":"Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: updated results of phase 1b\/2 study in advanced MSS CRC","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib126","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2025.43.16_suppl.3553","article-title":"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib127","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2026.108304_bib128","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.108304_bib129","article-title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: the phase 3, randomized KEYFORM-007 study","volume":"43","author":"Segal","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib130","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-25-0002","article-title":"Nivolumab and relatlimab for the treatment of patients with unresectable or metastatic mismatch repair-proficient colorectal cancer","volume":"31","author":"Christenson","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104204","article-title":"Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR\/MSS colorectal cancer: options and strategies","volume":"200","author":"Yang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2026.108304_bib132","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41416-024-02730-7","article-title":"Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"131","author":"Tsukada","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib133","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib134","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.108304_bib136","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib137","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/oncolo\/oyab046","article-title":"A randomized phase II trial of mFOLFOX6 + bevacizumab alone or with AdCEA vaccine + avelumab immunotherapy for untreated metastatic colorectal cancer","volume":"27","author":"Redman","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108304_bib138","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib139","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2026.108304_bib141","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib142","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41467-024-45960-2","article-title":"Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort","volume":"15","author":"Saeed","year":"2024","journal-title":"Nat Commun"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108304_bib143","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib144","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2023.41.16_suppl.3575","article-title":"Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: results of the phase II AVETRIC trial by GONO","volume":"41","author":"Conca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib145","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.2022.40.16_suppl.3595","article-title":"Interim analysis of the phase II AVETUXIRI trial: avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"40","author":"Huyghe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib146","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib147","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib148","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2024.42.16_suppl.2664","article-title":"Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors","volume":"42","author":"Patnaik","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108304_bib149","article-title":"618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer","volume":"34","author":"Kim","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2026.108304_bib150","doi-asserted-by":"crossref","first-page":"vi124","DOI":"10.1093\/annonc\/mdw368.32","article-title":"Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers","volume":"27","author":"McCaffery","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib151","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2026.108304_bib152","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib153","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11523-025-01130-y","article-title":"A phase 1b\/2 study of the anti-CD47 antibody magrolimab with cetuximab in patients with colorectal cancer and other solid tumors","volume":"20","author":"Eng","year":"2025","journal-title":"Target Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.108304_bib154","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.annonc.2025.05.022","article-title":"10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC)","volume":"36","author":"Yamaguchi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib155","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib156","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","article-title":"Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases","volume":"6","author":"Magee","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib157","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.2024.42.16_suppl.2518","article-title":"Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib158","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2023.41.16_suppl.3559","article-title":"Novel GUCY2C targeting CAR-T therapy: efficacy in advanced colorectal cancer","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib159","article-title":"A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer","volume":"42","author":"Schlechter","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib160","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1200\/JCO.2023.41.16_suppl.4034","article-title":"EpCAM CAR T (IMC001) for the treatment of advanced GI cancers","volume":"41","author":"Luo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib161","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.esmoop.2026.108304_bib162","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib163","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib164","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108304_bib165","article-title":"A phase 1\/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC)","volume":"41","author":"Desai","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib166","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO-24-02081","article-title":"Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy","volume":"43","author":"Ouladan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib167","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13148-024-01740-9","article-title":"Epigenetics and immunotherapy in colorectal cancer: progress and promise","volume":"16","author":"Dang","year":"2024","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.esmoop.2026.108304_bib168","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108304_bib169","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2026.108304_bib170","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108304_bib171","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13148-023-01485-x","article-title":"A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer","volume":"15","author":"Baretti","year":"2023","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.esmoop.2026.108304_bib172","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.it.2020.08.010","article-title":"Overcoming immune checkpoint blockade resistance via EZH2 inhibition","volume":"41","author":"Kim","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.esmoop.2026.108304_bib173","doi-asserted-by":"crossref","first-page":"53997","DOI":"10.18632\/oncotarget.9804","article-title":"Targeting BET bromodomain proteins in solid tumors","volume":"7","author":"Sahai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.108304_bib174","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2026.108304_bib175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib176","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","article-title":"PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer","volume":"76","author":"Nagarsheth","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib177","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2326-6066.CIR-22-0813","article-title":"SWI\/SNF complex genomic alterations as a predictive biomarker for response to immune checkpoint inhibitors in multiple cancers","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib178","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/v12080884","article-title":"Silencing and transcriptional regulation of endogenous retroviruses: an overview","volume":"12","author":"Geis","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.esmoop.2026.108304_bib179","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/849573","article-title":"Epigenetic control of interferon-gamma expression in CD8 T cells","volume":"2015","author":"de Ara\u00fajo-Souza","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.esmoop.2026.108304_bib180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2020.09.006","article-title":"The impact of ARID1A mutation on molecular characteristics in colorectal cancer","volume":"140","author":"Tokunaga","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib181","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/cas.15716","article-title":"Association of KMT2C\/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer","volume":"114","author":"Liu","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2026.108304_bib182","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3726595","article-title":"DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer","volume":"2017","author":"Leygo","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.esmoop.2026.108304_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188722","article-title":"DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer","volume":"1877","author":"M\u00fcller","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib184","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00428-007-0398-3","article-title":"CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma","volume":"450","author":"Ogino","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.esmoop.2026.108304_bib185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002671","article-title":"DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.108304_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.796647","article-title":"A pan-cancer analysis of predictive methylation signatures of response to cancer immunotherapy","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.108304_bib187","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s40425-019-0737-3","article-title":"Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers","volume":"7","author":"Wu","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108304_bib188","article-title":"725O Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: translational analyses of AtezoTRIBE and AVETRIC trials","volume":"36","author":"Carullo","year":"2025","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:33:56Z","timestamp":1787848436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":188,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022465"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108304","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAF","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108304"}}